Tiludronate or Skelid is indicated for Paget's disease, but it is being tested for osteoporosis.
Tiludronate or Skelid is a bisphosphonate which slows bone loss increasing bone density. It belongs to the same family as alendronate and etidronate.
Stomach irritation and bone pain are the most often reported side effects. Food interferes with its absorption - as with all bisphosphonates. Ideally it should be taken first thing in the morning on an empty stomach and with a full glass of water. Nothing should be eating for half to one hour afterwards and the individual should remain upright to improve absorption and avoid esophageal irritation.
There are no contraindications for Tiludronate or Skelid other than people who may be sensitive or allergic to the drug or components of the drug.
Because Tiludronate or Skelid promotes growth of bone, individuals must ensure that they have sufficient raw material with which the body can build bone, for example calcium. Any food or other medication can diminish Tiludronate or Skelid's absorption, thus it should not be taken at the same time as food or other medication.
Arthritis Rheum 1995;38:851
J Clinical Endo Metab 1996;81:961
NEJM 1997;336:558
Medical Letter 1997;39:65
The relevant product monographs must be regarded as the appropriate sources of prescribing information.